NEW YORK – Digital pathology firm Inspirata announced on Tuesday that it has partnered with King's Health Partners Experimental Cancer Medicine Centre and Guy's and St Thomas' NHS Foundation Trust to pilot its Trial Navigator software for clinical trials.
The organizations will use the software as part of an evaluation of how artificial intelligence-based automation can help with identification and efficiency of matching patients with cancer to early-phase clinical trials, Inspirata said in a statement.
Using oncology-specific natural language processing to evaluate a patient's individual medical reports and potential trial eligibility criteria, the pilot will look at how Trial Navigator can improve bottlenecks in identifying and matching patients to relevant clinical trials.
The software has been deployed at more than 400 hospitals and cancer centers globally and was designed to improve clinical trial matching by supporting the clinician at the point of care and trial coordinators with patient identification.
It can also be used to perform instantaneous look-ups against relevant trial databases, the company said.
"AI technology offers the potential to better match our patients to available trials, but we need to evaluate them first to prove that they can deliver on their promise," Danny Ruta, clinical artificial intelligence lead at Guy's and St Thomas' NHS Foundation Trust, said in a statement. "We hope that the intelligent automation afforded by Trial Navigator will prove to be an effective solution for identifying greater numbers of our eligible cancer patient population for clinical trials."
Last year, Inspirata partnered with Carebox Healthcare Solutions to develop a product for hospitals and oncologists that provides information on matching cancer patients with clinical trials.